News | July 04, 2023
Adare Pharma divests Adare Biome to dsm-firmenich
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22
Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
The Group will continue to make proactive investments of its management resources in the life science business
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore
APIC is a contract development and manufacturing organization (CDMO) that offers a wide range of services such as synthetic route design, pilot manufacturing, investigational medical manufacturing, and commercial production, by making full use of integrated processes that combine organic synthesis technologies and biotechnologies it has cultivated over many years
Both manufacturing facilities are based out of Benguluru, India
Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
Subscribe To Our Newsletter & Stay Updated
